The first federal vaccine push in the U.S. was the Act to Encourage Vaccination of 1813 – signed by President James Madison, which required free distribution of smallpox vaccine – according to historical accounts. The measure followed lobbying by James Smith, a physician known as the “Jenner of America,” who was appointed federal vaccine agent under the law.
Congress repealed the act in 1822 after safety failures and complaints of profiteering and corruption, the same accounts state. The repeal marked the first federal retreat from vaccine regulation in the nation’s history. The episode set a template that historians and critics say has repeated for more than two centuries: government promotion of vaccination, followed by documented safety failures and followed by public backlash.
Early Setbacks: Tarboro Tragedy and Civil War Vaccination Problems
The 1822 repeal followed what is known as the Tarboro Tragedy, in which Smith sent live smallpox virus instead of cowpox vaccine to North Carolina, causing about 60 infections and 10 deaths, according to the historical account. The incident is cited as an early example of distribution failures under a federal vaccine program.
Historian Terry Reimer wrote that “unfavorable results from vaccination, or spurious vaccinations, were all too common” during the Civil War, according to Brownstone Institute President Jeffrey A. Tucker. Reimer stated that syphilitic scabs and contaminated material spread disease, and that the Confederate Medical Department tried to limit soldier-to-soldier vaccination.
These 19th-century episodes illustrate a recurring theme that later critics of vaccine policy would cite. Safety problems were often documented only after widespread use, and official responses frequently came after public harm had occurred.
Biologics Control Act of 1902: Industry Initiative, Coleman Article Says
The Biologics Control Act of 1902, a foundational federal law governing vaccine and antitoxin production, was an initiative of the large biologics manufacturers, according to Terry S. Coleman’s 2016 article in the Food and Drug Law Journal titled “Early Developments in the Regulation of Biologics.” Coleman wrote that “the 1902 Act was an initiative of the large biologics manufacturers, and it was enacted with the secret cooperation of Public Health Service.”
According to the historical account, Parke-Davis pushed for strict standards and wrote to the Public Health Service, “As you are perhaps aware, the regulations cannot be too stringent for us.” The correspondence is cited as evidence that industry players sought regulation to stabilize markets and disadvantage smaller competitors.
Separately, investigative reporting published by The BMJ has found that regulatory agencies in six countries, including the United States, have seen large proportions of their budgets funded by the industry they are sworn to regulate, raising questions about independence. Maryanne Demasi, the investigative journalist behind the report, documented significant conflicts of interest between drugmakers and the agencies, according to the reporting [1][2][3].
Jacobson v. Massachusetts and the 1986 Liability Shield
In 1905, the Supreme Court decided Jacobson v. Massachusetts, upholding forced vaccination on public health grounds over freedom of conscience, according to the historical account. The ruling remains a foundational precedent for state vaccine mandates.
Eighty-one years later, the National Childhood Vaccine Injury Act of 1986 granted liability protection to makers of childhood schedule vaccines and moved injury claims out of civil courts into a specialized federal compensation program, according to the account. The law has been criticized by vaccine-injured families, who describe the National Vaccine Injury Compensation Program as “a fortress of opacity and resistance – a system that prioritizes protecting the pharmaceutical industry” over claimants [4].
According to Tucker, the 1980 Bayh-Dole Act enabled the National Institutes of Health to share patents with pharmaceutical companies, a policy shift with reported market value approaching $1 billion to $2 billion. The combination of liability protection, patent sharing and mandatory childhood schedules created what critics describe as a durable framework of industry-favorable regulation.
